Janus Henderson Group PLC Trims Stock Position in Aveanna Healthcare Holdings Inc. $AVAH

Janus Henderson Group PLC cut its stake in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) by 91.6% in the 1st quarter, Holdings Channel reports. The firm owned 23,600 shares of the company’s stock after selling 257,448 shares during the period. Janus Henderson Group PLC’s holdings in Aveanna Healthcare were worth $152,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Aveanna Healthcare by 38.0% during the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock valued at $45,564,000 after buying an additional 1,535,351 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Aveanna Healthcare by 49.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,334,374 shares of the company’s stock worth $8,593,000 after buying an additional 441,707 shares during the period. Smith Group Asset Management LLC boosted its position in Aveanna Healthcare by 34.3% during the 1st quarter. Smith Group Asset Management LLC now owns 263,669 shares of the company’s stock valued at $1,698,000 after acquiring an additional 67,393 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Aveanna Healthcare by 16.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 951,594 shares of the company’s stock valued at $6,128,000 after acquiring an additional 134,043 shares in the last quarter. Finally, Weiss Asset Management LP purchased a new position in shares of Aveanna Healthcare during the 1st quarter worth approximately $732,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVAH has been the subject of several research reports. Royal Bank Of Canada raised Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research report on Wednesday, June 3rd. Barclays upped their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Truist Financial increased their price objective on Aveanna Healthcare from $9.00 to $11.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. Finally, Stephens upgraded shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $10.00 to $11.00 in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.78.

Insider Buying and Selling

In related news, major shareholder J.H. Whitney Equity Partners V sold 2,419,035 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $8.01, for a total value of $19,376,470.35. Following the transaction, the insider owned 10,112,123 shares in the company, valued at $80,998,105.23. The trade was a 19.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patrick A. Cunningham sold 125,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $7.59, for a total transaction of $948,750.00. Following the sale, the insider directly owned 212,755 shares in the company, valued at $1,614,810.45. This trade represents a 37.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 31,305,664 shares of company stock valued at $215,555,910. Insiders own 5.30% of the company’s stock.

Aveanna Healthcare Stock Performance

Shares of AVAH opened at $8.95 on Wednesday. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 5.35. The business’s 50 day moving average price is $8.72 and its 200-day moving average price is $7.71. Aveanna Healthcare Holdings Inc. has a 52 week low of $5.93 and a 52 week high of $10.32. The stock has a market cap of $1.95 billion, a P/E ratio of 7.58, a P/E/G ratio of 0.94 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.05. The company had revenue of $647.91 million during the quarter, compared to analyst estimates of $613.22 million. Aveanna Healthcare had a return on equity of 124.68% and a net margin of 10.37%.The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Equities research analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.68 earnings per share for the current fiscal year.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.